Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
Delayed Quote. Delayed Nyse - 01/17 04:04:24 pm
88 USD   -1.41%
01/20ABBVIE : Form 8.3 - Abbvie Inc
DJ
01/17ABBVIE : Form 8.3 - -2-
DJ
01/17ABBVIE : Form 8.3 -
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/13/2020 01/14/2020 01/15/2020 01/16/2020 01/17/2020 Date
88.52(c) 88.2(c) 89.26(c) 89.26(c) 88(c) Last
9 298 850 8 877 304 8 490 129 7 073 377 10 122 317 Volume
-0.61% -0.36% +1.20% 0.00% -1.41% Change
More quotes
Financials (USD)
Sales 2019 33 271 M
EBIT 2019 15 768 M
Net income 2019 8 578 M
Debt 2019 30 704 M
Yield 2019 4,89%
Sales 2020 35 362 M
EBIT 2020 17 096 M
Net income 2020 10 741 M
Debt 2020 22 995 M
Yield 2020 5,43%
P/E ratio 2019 14,7x
P/E ratio 2020 9,62x
EV / Sales2019 4,83x
EV / Sales2020 4,33x
Capitalization 130 B
More Financials
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with... 
Sector
Pharmaceuticals
Calendar
02/07Earnings Release
More about the company
Surperformance© ratings of AbbVie Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE INC.
01/20ABBVIE : Form 8.3 - Abbvie Inc
DJ
01/17ABBVIE : Form 8.3 - -2-
DJ
01/17ABBVIE : Form 8.3 -
DJ
01/16ABBVIE : Form 8.3 - -2-
DJ
01/16ABBVIE : Form 8.3 -
DJ
01/15ABBVIE : Form 8.3 - -2-
DJ
01/15ABBVIE : Form 8.3 -
DJ
01/15ABBVIE : New Head-to-Head Phase 3 Data Show SKYRIZI Superior to Cosentyx across ..
AQ
01/15ABBVIE : Form 8.3 -
AQ
01/14ABBVIE : Shares Up; Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study
DJ
01/14UPDATE : Form 8.3 -AbbVie Inc -2-
DJ
01/14UPDATE : Form 8.3 -AbbVie Inc
DJ
01/14ABBVIE : Form 8.3 -AbbVie Inc
DJ
01/14ABBVIE : Skyrizi Met Endpoints in Phase 3 Plaque Psoriasis Study
DJ
01/14UPDATE : Form 8.3 -AbbVie Inc
AQ
More news
News in other languages on ABBVIE INC.
01/14ABBVIE : Ex-dividend day for
01/10L'essentiel de l'actualité économique à 21h00 (20h00 gmt)
01/10ALLERGAN : l'UE autorise le rachat par AbbVie
01/10ABBVIE : l'UE autorise le rachat d'Allergan
01/10RACHAT D'ALLERGAN PAR ABBVIE : feu vert sous condition de l'UE
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Sector news : Pharmaceuticals - NEC
01/20JPMorgan says 'oui' to Paris expansion post-Brexit
RE
01/20ALLERGAN : Form 8.3 - Allergan Plc
DJ
01/20BNP Paribas AM Launches World Climate Carbon Offset Plan Fund
DJ
01/20ASTRAZENECA : FDA Gives Orphan Drug Status to Two Liver Cancer Drugs
DJ
01/20ASTRAZENECA : Prostate Cancer Supplemental Drug Gets U.S. Approval
DJ
More sector news : Pharmaceuticals - NEC
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 95,67  $
Last Close Price 88,00  $
Spread / Highest target 47,7%
Spread / Average Target 8,71%
Spread / Lowest Target -7,95%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-0.61%130 136
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654